Rheum for Everyone, Episode 24 (video)| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Guidance

Subcategories:EthicsLegal UpdatesLegislation & AdvocacyResearch Rheum

Figure 2: High-resolution computed tomography showed evidence of interstitial lung disease.

High-resolution computed tomography shows evidence of ILD.

The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!

 

What Clinicians Should Know About Midfoot Osteoarthritis

Yvonne M. Golightly, PT, MS, PhD, Jill Halstead, BSc, MSc, PhD, MRCPod, John B. Arnold, PhD, Lara S. Chapman, MSc, BPod, Catherine J. Bowen, PhD, BPod, Marian T. Hannan, DSc, MPH, Hylton B. Menz, PhD, BPod, Kade L. Paterson, PhD, BPod, BAppSci(Hons) & Martin J. Thomas, PhD, MCSP  |  

Midfoot OA experts offer an overview of a common, but under-recognized, form of OA, & discuss quality of life impacts, treatments, clinical evaluation procedures & the critical need for further research.

Study: Are TNF Inhibitors Safe for Patients with RA-ILD?

Bryn Nelson, PhD  |  

Despite anecdotal reports to the contrary, a large observational study concludes that TNF inhibitors, compared with non-TNF biological or targeted synthetic DMARDs, do not cause higher rates of death or respiratory hospitalization in patients with RA-ILD.